Breast cancer (HER2-positive)
- HER2-targeted therapy is the treatment backbone
- Trastuzumab-based therapy for early and metastatic disease
- Add pertuzumab in selected higher-risk settings
- Antibody-drug conjugates are major later-line/selected early options
- Monitor LV function with HER2 therapy
- Endocrine therapy also matters if HR-positive
Use at a glance
- HER2-targeted therapy is the treatment backbone
Escalation / refractory disease
- Antibody-drug conjugates are major later-line/selected early options
Treatment options
- Trastuzumab-based therapy for early and metastatic disease
Choosing treatment
- Endocrine therapy also matters if HR-positive
Monitoring / follow-up
- Add pertuzumab in selected higher-risk settings
- Monitor LV function with HER2 therapy
Self-check
- What treats early and metastatic HER2-positive breast cancer?
Trastuzumab-based therapy. - What cardiac measure is monitored during HER2 therapy?
LV function.
Drugs used for this (1)
All clinical uses · Open Breast cancer (HER2-positive) in the interactive console ↗